Phuong N. Huynh

Array ( [id] => 8994522 [patent_doc_number] => 08518404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-27 [patent_title] => 'Activatable binding polypeptides and methods of identification and use thereof' [patent_app_type] => utility [patent_app_number] => 13/411409 [patent_app_country] => US [patent_app_date] => 2012-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 45 [patent_no_of_words] => 40818 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13411409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405912 [patent_doc_number] => 20120237977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'Activatable Binding Polypeptides and Methods of Identification and Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/411416 [patent_app_country] => US [patent_app_date] => 2012-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 40816 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13411416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8393194 [patent_doc_number] => 20120231035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-13 [patent_title] => 'METHOD FOR INDUCING CELL LYSIS WITH IMMUNOGENIC PORTIONS OF NY-ESO-1 PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/404633 [patent_app_country] => US [patent_app_date] => 2012-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8673 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13404633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11873616 [patent_doc_number] => 09745374 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-29 [patent_title] => 'Fusion proteins containing recombinant cytotoxic RNAses' [patent_app_type] => utility [patent_app_number] => 13/402480 [patent_app_country] => US [patent_app_date] => 2012-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 12309 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13402480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8975964 [patent_doc_number] => 20130209394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'MN/CA IX AND EGFR PATHWAY INHIBITION' [patent_app_type] => utility [patent_app_number] => 13/364871 [patent_app_country] => US [patent_app_date] => 2012-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18462 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13364871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9311260 [patent_doc_number] => 08652476 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-02-18 [patent_title] => 'Pharmaceutical composition for treating ischemic events' [patent_app_type] => utility [patent_app_number] => 13/359281 [patent_app_country] => US [patent_app_date] => 2012-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 12312 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13359281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8759567 [patent_doc_number] => 08420085 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-04-16 [patent_title] => 'Anti-IGF-IR antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/352976 [patent_app_country] => US [patent_app_date] => 2012-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 13406 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13352976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8347797 [patent_doc_number] => 20120208721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-16 [patent_title] => 'NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/352599 [patent_app_country] => US [patent_app_date] => 2012-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 50456 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13352599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10002444 [patent_doc_number] => 09046527 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Mutated SUMO isoforms and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/349459 [patent_app_country] => US [patent_app_date] => 2012-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 14613 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13349459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9777403 [patent_doc_number] => 08852603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-07 [patent_title] => 'Inhibition of secretion from non-neuronal cells' [patent_app_type] => utility [patent_app_number] => 13/344776 [patent_app_country] => US [patent_app_date] => 2012-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 19 [patent_no_of_words] => 21663 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13344776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8675000 [patent_doc_number] => 08383112 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-02-26 [patent_title] => 'Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases' [patent_app_type] => utility [patent_app_number] => 13/343493 [patent_app_country] => US [patent_app_date] => 2012-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24957 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13343493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8335124 [patent_doc_number] => 20120201827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-09 [patent_title] => 'ANTI-CD38 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/341860 [patent_app_country] => US [patent_app_date] => 2011-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 24514 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13341860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8278423 [patent_doc_number] => 20120172297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-05 [patent_title] => 'SYNTHETIC HUMAN GENES AND POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES' [patent_app_type] => utility [patent_app_number] => 13/340187 [patent_app_country] => US [patent_app_date] => 2011-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 97 [patent_figures_cnt] => 97 [patent_no_of_words] => 24102 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13340187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11297834 [patent_doc_number] => 09505830 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-29 [patent_title] => 'Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are obtained by means of mutagenesis of variable regions' [patent_app_type] => utility [patent_app_number] => 13/976060 [patent_app_country] => US [patent_app_date] => 2011-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 17674 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13976060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8523575 [patent_doc_number] => 20120322982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-20 [patent_title] => 'ANTI-VEGF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/335044 [patent_app_country] => US [patent_app_date] => 2011-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 53350 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13335044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11177964 [patent_doc_number] => 09409950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-09 [patent_title] => 'Linker peptides and polypeptides comprising same' [patent_app_type] => utility [patent_app_number] => 13/996918 [patent_app_country] => US [patent_app_date] => 2011-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 27087 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13996918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8139475 [patent_doc_number] => 20120094291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-19 [patent_title] => 'FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME' [patent_app_type] => utility [patent_app_number] => 13/327658 [patent_app_country] => US [patent_app_date] => 2011-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19895 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0094/20120094291.pdf [firstpage_image] =>[orig_patent_app_number] => 13327658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8289790 [patent_doc_number] => 20120178106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-12 [patent_title] => 'ANTIGEN BINDING MOLECULES THAT BIND EGFR, VECTORS ENCODING SAME, AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/315989 [patent_app_country] => US [patent_app_date] => 2011-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 48318 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13315989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8240341 [patent_doc_number] => 20120149061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-14 [patent_title] => 'Modified Antibody Compositions, Methods of Making and Using Thereof' [patent_app_type] => utility [patent_app_number] => 13/315623 [patent_app_country] => US [patent_app_date] => 2011-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 50592 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13315623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8393149 [patent_doc_number] => 20120230992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-13 [patent_title] => 'VEGF-RELATED PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/315109 [patent_app_country] => US [patent_app_date] => 2011-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 25938 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13315109 [rel_patent_id] =>[rel_patent_doc_number] =>)